Psychiatr. pro Praxi, 2002; 3: 132-134

Sledovanie vedľajších účinkov v liečbe neuroleptikami

MUDr. Radovan Vaškovský
Psychiatrické oddelenie, Fakultná nemocnica Nitra

Published: December 31, 2002  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vaškovský R. Sledovanie vedľajších účinkov v liečbe neuroleptikami. Psychiatr. praxi. 2002;3(3):132-134.

Výskyt vedľajších účinkov pri akejkoľvek liečbe znamená možnú zníženú compliance pacienta a tým i výsledného efektu liečby. Z pohľadu psychiatra to znamená nedostatočne liečeného pacienta s príznakmi duševného ochorenia. Výskyt extrapyramídového syndrómu je jedným s najčastejších vedľajších príznakov, s ktorým sa stretávame v liečbe neuroleptikami. Práca hodnotí ich častosť vrámci diagnostických kategórií, v závislosti na type a dávke podávaných neuroleptík, ako aj na dĺžke liečby a na veku pacienta. Zároveň hodnotí postupy a stratégiu liečby, ktorú sme pre výskyt vedľajšieho účinku uskutočnili.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Beasley CM, Dellva MA, Tamura RN, Morgenstern H, Glazer WM, Ferguson K, Tollefson GD. Randomized double-blind comparison of the incidence of tardive dyskinesia in patients with schizofrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 1999; 174: 23-30. Go to original source... Go to PubMed...
    2. Cooper SJ, Butler A, Tweed J, Welch C, Rainwalla J. Zotepine in the prevention of recurrence: a randomised, doble-blind, placebo-controlled study for chronic schizophrenia. Psychopharmacology 2000; 150: 237-243. Go to original source... Go to PubMed...
    3. Dickson RA, Glazer WM. Neuroleptic-induced hyperprolactinemia, Schizophrenia Research 1999; 35, 75-86. Go to original source... Go to PubMed...
    4. Hanušková V. Hladina prolaktinu a léčba neuroleptiky. Psychiatrie pro praxi 2000; 1: 7-10.
    5. Gelder GM, Mayou R, Cowen P. Shorter Oxford Textbook of Psychiatry. Oxford University Press 2001; 1075 s.
    6. Gelder GM, López-Ibor JJ, Andreasen N. New Oxford Textbook of Psychiatry. Oxford University 2000; Press, 2230 s.
    7. Kogeorgos J, Kanellos P, Michalakeas A, Joannidis J: Sulpiride and risperidone vs., ,classical" neuroleptics in schizophrenia: A follow-up study. Eur Neuropsychopharmacol 1995; 5(Suppl): 335-336. Go to original source... Go to PubMed...
    8. Kolibáš E, Kořínková V. Schizofrénia a poruchy z jej okruhu. Vydavateľstvo Asklepios, Bratislava 1998: 91 s.
    9. Lindenmayer JP. Risperidone: Efficacy and side effects. J Clin Psychiat Monograph 1994; 12: 53-58.
    10. Maršálek M: Extrapyramidové poruchy vyvolané léky, diagnostika, léčba, prevence. Psychiatrie pro praxi 2000; 1: 18-20.
    11. Owens DGG: Extrapyramidal side effects and tolerability of risperidone: A review. J Clin Psychiat 1994; 55(Suppl 5): 29-35.
    12. Petty RG. Prolactin and antipsychotic medication:mechanism of action, Schizophrenia Research 1999; 35: 67-73. Go to original source... Go to PubMed...
    13. Seifertová D. Nově registrovaná antipsychotika. Psychiatrie pro praxi 2001; 1: 20-24.
    14. Švestka J. Nová antipsychotika II. generace: Olanzapin. Psychiatrie 1998; 2: 115-123.
    15. Švestka J. Clozapin. Prototyp antipsychotik nové generace. Praha: Maxdorf, 1998.
    16. Švestka J. Atypická neuroleptika - rozdělení dle mechanizmu účinku, operacionální definice, kritéria, záměna. Psychiatrie pro praxi 2001; 1: 35-36.
    17. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C, Tollefson GD. Double-blind comparison of olanzapine versus risperidone in the tratment of schizophrenia and other psychotic disorders. J Clin Psychopharm 1997; 17: 407-418. Go to original source... Go to PubMed...
    18. Vaškovský R. Výskyt extrapyramídovej symptomatológie pri neuroleptickej liečbe. Možnosti a spôsoby jej ovplyvnenia v našich podmienkach. Psychiatria 2001; 8, 1: 30-33.

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.